Neurogenesis in the adult brain is now well established since its first report 40 years ago ([@bib2]). Two regions, the subventricular zone and the dentate gyrus of the hippocampus, are known to produce new neurons throughout life ([@bib8], [@bib10]). Neuron formation during adulthood occurs in diverse species including rodents ([@bib8]), monkeys ([@bib17]) and humans ([@bib13]). The hippocampus is a structure involved in memory formation ([@bib24]), consolidation ([@bib34]) and retrieval ([@bib11]), and such functions have raised the possibility that constitutively produced new neurons may play crucial roles in learning and memory ([@bib25]). Since drugs known to be effective antidepressants stimulate neurogenesis ([@bib38]), there is recent clinical interest in the possibility that either the onset of depression or its treatment may be associated with changes in neurogenesis in the dentate gyrus ([@bib40], [@bib32]).

A wide range of factors has been shown to regulate adult neurogenesis. Learning ([@bib16]), experience ([@bib26]), neural injuries ([@bib30], [@bib22]) and growth factors ([@bib28], [@bib1]) stimulate neurogenesis while ageing ([@bib27]), psychological/physical stress ([@bib19], [@bib37]), radiation ([@bib36]), alcohol ([@bib35]) and many others suppress this process.

The fate of progenitors in the dentate gyrus can be classified into three distinct stages: proliferation, survival and differentiation. Progenitor cells divide and give rise to daughter cells which form clusters at the subgranular zone of the dentate gyrus. A proportion of these newly-formed cells undergo apoptosis and only about half of them survive ([@bib46]). The surviving progenitors then differentiate into neurons, glia and other cell types ([@bib33]). Modulators of neurogenesis may affect a particular developmental stage ([@bib26]), and therefore it is important to study the three stages separately in order to understand how the production of neurons is regulated in the adult brain.

Glucocorticoids (cortisol in humans, or corticosterone in rodents) are adrenal-derived steroids. Glucocorticoids enter the brain through the blood--brain barrier, and their levels are heightened during stressful events. Raised levels of glucocorticoids suppress proliferation of progenitor cells in the dentate gyrus, while removal of glucocorticoids by adrenalectomy (ADX) stimulates this process ([@bib18], [@bib5]). In our recent report ([@bib46]), we demonstrated that in addition to glucocorticoids' effects on proliferation, raised levels reduced survival of newly-formed cells and a glucocorticoid-free environment promoted survival of these cells. However, whether glucocorticoids regulate differentiation of progenitor cells in the adult hippocampus has not been studied.

Experimental procedures
=======================

Animals
-------

All procedures were carried out under Home Office (UK) license and guidelines. These stipulate the minimal use of animals and procedures required to minimize pain and suffering. Lister hooded male rats (Harlan, Bicester, UK), weighing around 250--300g at the beginning of the experiment, were used. Rats were housed three--four per cage on reversed 12-h light/dark cycles (lights off at 11:00 h). Ambient temperature was maintained at 21°±2°C. Food and water were available *ad libitum*. All surgeries were carried out under general anesthesia. ADX animals were given a choice of 0.9% saline and water to replenish salt loss.

BrdU injection and corticosterone level manipulations
-----------------------------------------------------

5-bromodeoxyuridine (BrdU) (Sigma), a thymidine analog incorporated into dividing cells during DNA synthetic phase (S-phase) of the cell cycle, was dissolved in 0.9% saline and injected i.p. (200mg/kg) at midday. A single BrdU injection paradigm was chosen to ensure that the population of cells labeled would come from the same time frame, and thus all newborn cells are in the same developmental phase at the start of the drug treatment.

To remove circulating glucocorticoids, bilateral ADX was performed under isoflurane anesthesia. Basal levels of corticosterone were replaced with s.c. implants of 1:1 corticosterone/cholesterol (Sigma) melted and molded into pellets weighing 200--220 mg. To increase plasma corticosterone above 'basal' levels, animals were given additional s.c. injections of corticosterone suspended in peanut oil at 40mg/kg/day, a dose shown to reduce neurogenesis. Reference plasma corticosterone levels of these different paradigms can be obtained in our recent publication ([@bib47]).

Experimental procedures
-----------------------

### Experiment 1

Thirty animals, given a single injection of BrdU, were divided into three groups. Group 1 (*n*=6) was killed 24 h after the BrdU injection. Group 2 (*n*=12) received a daily injection of peanut oil, beginning 24 h after BrdU. Group 3 (*n*=12) received 40mg/kg/day corticosterone suspended in peanut oil. Animals (*n*=6) from each treatment group (2 and 3) were sampled at seven and 28 days after BrdU ([Fig. 1](#fig1){ref-type="fig"}d).

### Experiment 2

Fifty-six intact rats were given BrdU as above, and then received various regimens of daily s.c. injections of either corticosterone (40mg/kg/day) or oil for 27 days. They were divided into seven groups of eight rats each. Group 1 received oil throughout. The next three groups received corticosterone for 9 days each, or oil otherwise. The start of corticosterone was staggered by nine days in each group (group two days 1--9, group three days 10--18, group four days 19--27). Group five received CORT on days 1--18, group six days 10--27, and group seven days 1--27. All rats were killed on day 28 ([Fig. 2](#fig2){ref-type="fig"}a).

### Experiment 3

Rats were divided into two major groups (*n*=24 each). The first group was given daily oil injections for 10 days (pre-treatment), and then two injections of BrdU, 3 h apart, on day 10. This double injection protocol served to label a larger pool of proliferating cells to compensate for the suppressive effect of corticosterone on cell division. The second group (*n*=24) was given daily injections of corticosterone (40mg/kg/day) for 10 days, and BrdU as above. Each group was then divided into three sub-groups. Groups 1a and 2a were killed 24 h after the BrdU injection. Groups 1b and 2b were given another 28 days (post-treatment) of oil injections. Groups 1c and 2c were given 28 days of corticosterone (40mg/kg/day). The latter four sub-groups were perfused 24 h after the last injection (day 29) ([Fig. 3](#fig3){ref-type="fig"}a).

### Experiment 4

Four groups of animals were used in this experiment (*n*=56). They all received a single injection of BrdU (200mg/kg, i.p.) to label the new-born cells. In group 1 (*n*=8), animals were killed 24 h after BrdU labeling, whereas in group 2 (*n*=16) they were sham-operated 24 h after BrdU and implanted s.c. with a cholesterol pellet. Eight rats were perfused at seven and 28 days after surgery. Group 3 (*n*=16) was bilaterally ADX 24 h after BrdU and implanted with a cholesterol pellet. Rats (*n*=8) were sampled at the same intervals. Group four (*n*=16) were also ADX, but received a 50% corticosterone pellet (200--250 mg). They were sampled at the same intervals ([Fig. 4](#fig4){ref-type="fig"}a).

### Experiment 5

All rats were adrenalectomized (ADX) (*n*=48), half were given basal corticosterone replacement (s.c. implant of 50% corticosterone pellet) and the others received a cholesterol pellet. Ten days after surgery, all animals received a single injection of BrdU. Each of the two original groups was divided into three sub-groups. The first two sub-groups (1a, 2a: *n*=8 per group) were killed 24 h after the BrdU injection. The second sub-groups (1b, 2b: *n*=8) had their corticosterone or cholesterol pellets removed and replaced with new, corticosterone pellet 24 h after BrdU. The third sub-groups (1c, 2c; *n*=8) had their corticosterone or cholesterol pellets removed and replaced with cholesterol pellets. Sub-groups b and c were perfused 29 days after BrdU ([Fig. 5](#fig5){ref-type="fig"}a).

Fluorescence immunochemistry
----------------------------

Animals were given an overdose of pentobarbitone sodium and perfused transcardially with 0.1M PB followed by 4% paraformaldehyde in 0.01M KPBS (pH 7.4). Brains were removed, post-fixed for 4 h, and then immersed in 20% sucrose in KPBS overnight for cryoprotection against formation of water ice crystals during freezing. Coronal sections were cut using a freezing microtome through the entire dentate gyrus at 40μm and sections were stored in anti-freeze (1:1:2 glycerol:ethyleneglycol:0.1M PBS). All rinses were done in 0.01M KPBS. Sections were first incubated in 2 N HCl at 37°C, and incubated overnight at room temperature with rat anti-BrdU antibody (1:200, Accurate, USA) in 0.2% Triton-X (Sigma, UK) and 5% normal goat serum (Vector Laboratories, USA). The sections were rinsed, and incubated in Rodamine-RX conjugated anti-rat secondary antibodies (1:800; Jackson Laboratories, USA) for 60 min. Antibodies against doublecortin (DCX; marker for immature neuron; mouse; 1:500, Santa Cruz Biotechnology, USA), NeuN (marker for mature neuron; mouse; 1:800; Chemicon, USA) and GFAP (glial marker; rabbit; 1:200; Sigma) were applied in combination depending on the time-point examined and incubated overnight at room temperature. Alexa-488 conjugated anti-mouse (1:500; Molecular Probes, USA) or Alexa-647 conjugated anti-rabbit antibodies (1:500; Molecular Probes) were used in according to the primaries used. Sections were then mounted on to polylysine-coated slides and coverslipped with Vectamount (Vector Laboratories).

Phenotype determination
-----------------------

All slides were randomized and coded prior to phenotype analysis. Analysis was performed using a Zeiss Axioskop 2 fluorescence microscope (Zeiss, Germany). A 10-layer Z-stack (0.762μm apart) with images from each color channel was captured with a 24-bit black/white digital camera using a 40× objective. Z-stacks were then deconvolved using Zeiss deconvolution software (a mathematical reconstruction model) to remove haze from adjacent sections. At least 30 BrdU cells from each brain were analyzed. Percentage neuronal differentiation was obtained from dividing the number of cells positive for neuronal marker by total number of cells analyzed.

Estimation of total number of new Neu-N-stained neurons
-------------------------------------------------------

The total number of new neurons in the sections examined was estimated using the following equation: $$N_{\text{E}_{\text{st}}} = N_{0} \times \%_{\text{Sur}} \times \%_{\text{Diff}}$$ where *N*~Est~ represents the total number of new neurons; *N*~0~ refers to the number of cells labeled by BrdU 24 h after labeling; %~Sur~ is the number of surviving BrdU cells expressed as percentage of mean BrdU cell count 24 h after labeling presented in our previous report ([@bib46]) and summarized in [Table 1](#tbl1){ref-type="table"}; %~Diff~ represents the percentage of BrdU cells positive for the mature neuronal marker NeuN. The number of new neurons in the brain sections sampled for a particular animal was calculated using the corresponding survival and differentiation percentages.

Statistical analysis
--------------------

Data were analyzed by one, two or three-way ANOVA; all data presented as percentages were arcsine transformed before statistical analysis. Instances in which non-parametric tests were used are specified in the results section.

Results
=======

Experiment 1: post-mitotic corticosterone reduced neuronal differentiation
--------------------------------------------------------------------------

Sections from animals killed on day-7 post-BrdU were triple-stained for BrdU, DCX and GFAP. A BrdU/DCX double positive cell is shown in [Fig. 1](#fig1){ref-type="fig"}a. [Fig. 1](#fig1){ref-type="fig"}e shows that corticosterone treatment for 7 days significantly reduced the percentage of BrdU cells immuno-positive for DCX at this time point (one-way ANOVA; *F*~1,11~=6.04, *P*\<0.03). Corticosterone had no effect on differentiation into GFAP-stained cells (GFAP: *F*~1,11~=0.06, *P*=0.82). BrdU/NeuN and BrdU/GFAP cells are shown in [Fig. 1](#fig1){ref-type="fig"}b and c, respectively. Corticosterone also significantly reduced the percentage of BrdU cells immuno-positive for NeuN (*F*~1,11~=30.8, *P*\<0.0001, [Fig. 1](#fig1){ref-type="fig"}f) and GFAP (*F*~1,11~=5.54, *P*\<0.043) at day 28. To reveal whether this represented a delay in maturation, day 28 sections were triple-stained for BrdU/DCX/GFAP. There was no difference in percentage of BrdU-stained cells immuno-positive for DCX or GFAP or those staining for neither after corticosterone treatment (DCX: *F*~1,11~=1.43, *P*=0.26; GFAP: *F*~1,11~=0.14, *P*=0.72; neither: *F*~1,11~=2.15, *P*=0.18) ([Fig. 1](#fig1){ref-type="fig"}g). Combining the survival data in [Table 1](#tbl1){ref-type="table"} and these data showed that the total number of new neurons was reduced by corticosterone treatment for 28 days (*F*~1,11~=14.4, *P*\<0.004).

Experiment 2: time-dependency of the effect of corticosterone on neuronal differentiation
-----------------------------------------------------------------------------------------

Brain sections from all seven groups were triple stained for BrdU/NeuN/GFAP. [Fig. 2](#fig2){ref-type="fig"}b shows the phenotypes of the BrdU-positive cells by percentage for each group. Three-way ANOVA, with each period as the independent variable, showed that all three corticosterone treatment periods altered the phenotypes of the BrdU-stained cells (0--9: *F*~2,55~=5.51, *P*\<0.023; 10--18: *F*~2,55~=5.74, *P*\<0.021; 19--27: *F*~2,55~=15.9, *P*\<0.0001), and that there was no interaction between the three treatment periods.

As expected from experiment 1, animals receiving 27 days of corticosterone had significantly lower percentage of NeuN positive BrdU-stained cells compared with animals receiving oil (one-way ANOVA, *F*~1,15~=43.6, *P*\<0.0001). One-way ANOVA also revealed that corticosterone treatment during period 1 or 2 alone had no effect on the percentage of BrdU-stained cells expressing NeuN relative to the Oil group (1: *F*~1,15~=0.93, *P*=0.35; 2: *F*~1,15~=4.00, *P*=0.07). However, treatment during period 3 alone significantly reduced this percentage (*F*~1,15~=6.81, *P*\<0.02). Although corticosterone treatment during period 1 or 2 had no significant effect on the phenotype of BrdU cells, when animals were treated with corticosterone during both periods 1 and 2, the percentage of BrdU/NeuN cells was significantly lowered (*F*~1,15~=9.43, *P*\<0.009). This is also true of those receiving corticosterone during both periods 2 and 3 (*F*~1,15~=12.8, *P*\<0.003). There was no detectable difference in GFAP phenotype (1: *F*~2,55~=0.24, *P*\<0.88; 2: *F*~2,55~=0.34, *P*\<0.57; 3: *F*~2,55~=0.021, *P*\<0.89), and thus the proportion of BrdU-stained cells also immuno-reactive for NeuN correlates negatively with those that express neither NeuN nor GFAP.

The total numbers of new neurons being formed in the different treatment groups are shown in [Fig. 2](#fig2){ref-type="fig"}c. One-way ANOVA and post hoc comparisons of the seven groups showed that the none of the single 9-day corticosterone treatment had an effect (Bonferroni; 1: *P*=1.00; 2: *P*=1.00; 3: *P*=1.00), but both the 18-day and 27-day corticosterone treatments significantly reduced neuronal production (1+2: *P*\<0.001; 2+3: *P*\<0.002; 1+2+3: *P*\<0.0001).

Experiment 3: effect of high levels of corticosterone prior to progenitor proliferation on neuronal differentiation
-------------------------------------------------------------------------------------------------------------------

In this experiment, animals received CORT either before or after BrdU labeling, or during both periods (see [Fig. 3](#fig3){ref-type="fig"}a). The percentages of each cell type for each group are shown in [Fig. 3](#fig3){ref-type="fig"}b. Corticosterone given both pre- and post-BrdU reduced NeuN phenotype. (Pre-treatment: *F*~1,\ 31~=9.73, *P*\<0.005; *F*~1,31~=56.88, *P*\<0.0001.) One-way ANOVA of the four groups demonstrated that corticosterone treatment significantly affected the percentage of BrdU-stained cells expressing NeuN (*F*~3,31~=24.8, *P*\<0.0001) but did not alter the proportion of cells immuno-positive for GFAP (*F*~3,31~=0.52, *P*\<0.67). Post hoc pair-wise comparisons showed that corticosterone pre-treatment reduced the percentage of BrdU/NeuN cells (Oil/Oil vs CORT/Oil; Bonferroni, *P*\<0.041). Post-treatment with corticosterone irrespective of the pre-treatment significantly reduced the BrdU/NeuN percentage (Bonferroni, Oil/Oil vs Oil/CORT, ^†^*P*\<0.0001; CORT/Oil Vs CORT/CORT, ^‡^*P*\<0.002). There was no significant difference between the Oil/CORT and CORT/CORT groups (*P*=1.00). Importantly, the effect of post-mitotic corticosterone on neuronal differentiation was more pronounced than that of pre-mitotic treatment corticosterone (Oil/CORT vs CORT/Oil: *P*\<0.040).

The total numbers of neurons generated from the four different paradigms are shown in [Fig. 3](#fig3){ref-type="fig"}c. Two-way ANOVA showed that corticosterone, both pre-treatment and post-treatment, significantly affected neuronal production (pre-treatment: *F*~3,31~=114.6, *P*\<0.0001, post-treatment: *F*~3,31~=62.0, *P*\<0.0001). There was an interaction between the two treatments (*F*~3,31~=40.9, *P*\<0.0001). Post hoc analysis showed that animals receiving corticosterone treatment, whether before or after BrdU injection, had significantly fewer new neurons (Oil/CORT; *P*\<0.0001; CORT/Oil: *P*\<0.0001; CORT/CORT: *P*\<0.0001). Treating animals with corticosterone before BrdU resulted in fewer new neurons than treatment with corticosterone after BrdU (CORT/Oil vs Oil/CORT: *P*\<0.021).

Experiment 4: effect of removal of endogenous glucocorticoids by ADX on neuronal differentiation
------------------------------------------------------------------------------------------------

BrdU/DCX/GFAP-stained brain sections at day 7 from the three treatment groups were analyzed and the percentages of BrdU-stained cells immuno-positive for DCX, GFAP or neither are shown in [Fig. 4](#fig4){ref-type="fig"}b. One-way ANOVA showed that there was no difference between the three treatment groups in the percentages of BrdU-positive cells also positive for DCX, GFAP or neither (DCX: *F*~2,23~=0.053, *P*=0.95; GFAP: *F*~2,23~=2.00, *P*=0.16; Neither: *F*~2,23~=0.46, *P*=0.64). Sections from the day 28 survival groups were stained for BrdU/NeuN/GFAP. One-way ANOVA of the three treatment groups ([Fig. 4](#fig4){ref-type="fig"}c) showed no difference in the phenotypes of the BrdU-stained cells after treatment (NeuN: *F*~2,23~=1.21, *P*=0.32; GFAP: *F*~2,23~=0.98, *P*=0.40; Neither: *F*~2,23~=2.97, *P*=0.08). The number of new neurons formed in each group was estimated using both the survival and differentiation data, and are shown in [Fig. 4](#fig4){ref-type="fig"}d. One-way ANOVA and post hoc analysis showed that post-mitotic ADX significantly increased the total number of new neurons formed in the dentate gyrus (Bonferroni; *P*\<0.025).

Experiment 5: effect of a corticoid-free environment during proliferation
-------------------------------------------------------------------------

Phenotypic analysis of the four day 28 survival groups showed no difference in the phenotype of the BrdU-stained cells between the four treatments ([Fig. 5](#fig5){ref-type="fig"}b, one-way ANOVA, NeuN: *F*~3,31~=0.227, *P*=0.88; GFAP: *F*~3,31~=1.32, *P*=0.29; neither: *F*~3,31~=0.30, *P*=0.82). Estimating the total number of new neurons formed using the survival and differentiation data revealed an interesting trend ([Fig. 5](#fig5){ref-type="fig"}c); two-way ANOVA demonstrated that both pre-treatment and post-treatment were effective (Pre: *F*~3,23~=31.6, *P*\<0.0001; Post: *F*~3,23~=10.2, *P*\<0.003). There was no interaction between the two (*F*~3,23~=1.98, *P*=0.171). One-way ANOVA and post hoc analysis demonstrated that all non-corticosterone-replaced groups, either before or after BrdU, had higher numbers of new neurons 28 days after BrdU (CORT/Chol: ^§^*P*\<0.034; Chol/CORT: ^†^*P*\<0.009; Chol/Chol: ^‡^*P*\<0.0001). A corticoid-free environment before BrdU labeling generated more neurons than a corticoid-free environment after BrdU labeling (Chol/CORT vs CORT/Chol: *P*\<0.034).

Discussion
==========

Development of progenitors in the dentate gyrus can be divided into three distinct stages: proliferation, survival and differentiation. The effect of glucocorticoids, especially that of corticosterone, on the first two stages has been demonstrated previously ([@bib18], [@bib5], [@bib46]). In this report, we provide findings that fill a missing and crucial part of the developmental trajectory of progenitor cells residing in the dentate gyrus. Using fluorescence immunochemistry and cell-type specific markers, we show that corticosterone regulates the phenotype of the newly-formed cells in the dentate gyrus.

Experiment 1 showed that in addition to its depressive action on proliferation and survival, corticosterone given during the post-mitotic interval also reduces differentiation of the newly-formed cells into mature neurons. This could be demonstrated both at the day-7 and day-28 time points, at which time immature (DCX) and mature (NeuN) neuronal markers respectively are maximally expressed. The reduction in neuronal differentiation can be accounted for in two ways. Firstly, corticosterone may halt the differentiation process of certain populations of newly-formed cells, and thus the proportion (fate) of BrdU-positive cells also positive for these neuronal markers will be lower at any given time after BrdU labeling. Secondly, corticosterone may slow down the differentiation process, thereby introducing a 'differentiation lag' in this process. To clarify this, sections from the day-28 time point were triple-stained for the immature neuronal marker DCX because only a small proportion of newly-formed cells would be expected to express this marker at day-28 ([@bib4]). If the observed reduction in neuronal differentiation after corticosterone was a consequence of a time window shift, one would expect to find a higher percentage of BrdU/DCX cells at the day-28 time point. However, our data suggested that this was not the case. Therefore, it is likely that corticosterone may convey a 'stop' signal to the differentiation process of the newly-formed cells, thus resulting in a decline in neuronal differentiation. Combining the survival data from our previous report ([@bib46]) with the differentiation data we present here, high levels of corticosterone present after progenitor division significantly lowered the number of new neurons formed in the samples we took of the dentate gyrus of the hippocampus. Since we have no data on rates of degeneration, it is also possible that increased apoptosis of maturing cells may contribute to the effects we describe here. A proportion of BrdU-labeled cells stained neither for GFAP, NeuN or DCX. The identity of these cells remains unknown, but the most likely explanation is that they are undifferentiated progenitor cells.

The regulation by corticosterone can be both direct (through receptors) and indirect, and candidates that mediate the effect of corticosterone include insulin-like growth factor-1 (IGF-1), brain-derived neurotrophin factor (BDNF), and epidermal growth factor (EGF), all of which have been shown to positively regulate adult neurogenesis and differentiation of progenitor cells ([@bib28], [@bib1], [@bib29]). Glucocorticoids may alter neuronal differentiation via suppression of these pathways since glucocorticoids negatively modulate the expression of these signaling molecules and their receptors ([@bib23], [@bib42], [@bib20]). The mechanism by which corticosterone regulates neuronal differentiation remains to be investigated.

There was an interesting difference between time-dependent actions of corticosterone on survival or differentiation of new cells. We showed previously that excess corticosterone given for 9 days during the first 18 days reduced survival, whereas treatment during the final 9 days did not. In contrast, this treatment regimen had no effect on the development of a neuronal phenotype, whereas corticosterone given during the final 9 days of the 28 day survival interval was effective. This suggests that there is a distinction between the corticoid-responsive processes regulating the two events, though the exact nature of either is still to be uncovered. Raised corticosterone, it seems, exerts maximal effect on survival during the early stages of progenitor development while its effect on differentiation is most powerful at a later stage. Combining the differentiation and survival data ([@bib46]) revealed that none of the 9-day treatment groups significantly reduced the total number of new neurons produced, but animals receiving corticosterone for 18 days or more resulted in significantly fewer neurons being produced.

High levels of corticosterone present prior to BrdU administration also reduced subsequent neuronal differentiation, as shown by experiment 3. Corticosterone treatment during the post-mitotic period in the experiment also reduced neuronal differentiation, confirming the results of the previous experiments. Interestingly, treating animals with corticosterone before progenitor proliferation also reduced the proportion of BrdU cells expressing the mature neuronal marker 28 days after labeling, irrespective of the treatment during the post-mitotic period. However, it is noteworthy that the suppressive effect of corticosterone on differentiation is stronger during the post-mitotic period. These actions are likely to be direct, since newly-formed cells express corticoid receptors at birth and the expression of these receptors increases over time ([@bib14]). However, any effect by glucocorticoids prior to progenitor division and during the early stages of development of these cells (when receptor expression is still low) are likely to be mediated by the surrounding local environment. Toward the day 28 time point, more differentiated cells may express corticoid receptors, so that the fact that post-mitotic corticosterone had a more prominent effect is possibly due to the increased sensitivity of more mature newly-formed cells to corticosterone from 19 to 27 days after birth. Nonetheless, estimation of total neuron production revealed that corticosterone treatment before progenitor division resulted in fewer neurons compared with animals receiving corticosterone during the post-mitotic period only. Combining the two treatments showed that neuron production in animals receiving corticosterone in both periods was merely 3.7% that of the control group.

Thus far, data in the literature and this report suggest that raised corticosterone is detrimental to all three stages of neurogenesis, proliferation, survival and differentiation, and that raised corticosterone reduces the number of neurons produced consequentially. Removal of glucocorticoids by ADX, on the other hand, positively regulates proliferation and survival of the progenitor cells ([@bib46]). However, triple staining in this report showed that ADX, and thus a relatively corticoid-free environment, did not favor increased proportional differentiation of newly-formed cells into neurons (experiments 4 and 5). Nonetheless, a corticoid-free environment during the post-mitotic period resulted in high number of neurons since overall survival is increased. Removal of glucocorticoids during both periods resulted in a 92.7% increase in the total number of new neurons in the sampled region relative to the control group. Although there is no evidence thus far to demonstrate that daily fluctuation of plasma corticoid levels would affect neurogenesis, it is important to note that high levels of glucocorticoids, as a result of physical or psychological stress, may have serious consequences on neurogenesis in the hippocampus. The dose of additional corticosterone we used (40mg/kg/day) is supra-physiological, and well into the 'stress' range. Ageing is also accompanied by raised circulating glucocorticoids ([@bib39], [@bib31]) and it has been shown that hippocampal neurogenesis is reduced at old age, but data also exist to support manipulation of corticoid (by ADX) could reverse this suppression ([@bib7]).

A large body of literature suggests that excess corticosterone is detrimental to hippocampal functions such as working and spatial memories ([@bib9], [@bib48]). If new neurons in the adult hippocampus are indeed responsible for the formation of new memory ([@bib43]), the reduction after corticosterone may account for the behavioral deficits observed in the learning models. Nonetheless, it is of immense interest to investigate whether a change in the number of new neurons in the dentate gyrus predicts a decline in hippocampal function, since new neurons numbers may be associated with synaptic changes and other molecular events such as LTP and LDP. Removal of glucocorticoids by ADX also impairs hippocampal-dependent learning ([@bib3], [@bib45]) and this is reversed by corticosterone replacement ([@bib44]). Moreover, ADX causes dramatic cell death in the granule cell layer ([@bib6]). Our observed increase in neuronal production in ADX animals may serve to compensate for this extensive loss. Whether the rate of ADX-induced cell loss is greater than the accompanying increase in new neuronal production, such that a net loss of granular neurons accounts for the decline in function, awaits further study.

The finding that glucocorticoids regulate neuronal differentiation in the dentate gyrus of the adult rat has important implications for those interested in the effects of stress on brain structure and function. This also provides further support for the recent suggestions that adult neurogenesis may be concerned with the psychopathology of major depressive disorder, a condition in which elevated glucocorticoids have been associated both as a risk factor for this condition, as well as one manifestation of the disease process itself ([@bib15], [@bib21], [@bib12], [@bib40]).
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![The morphology of (a) a BrdU/DCX double positive cell, (b) a BrdU/NeuN double positive cell, (c) a BrdU/GFAP double positive cell. (d) Design of experiment 1. (e) The percentage of phenotypes of BrdU-labeled cells at day 7. Corticosterone treatment significantly reduced the percentage of BrdU cells positive for the immature neuronal marker DCX at this time-point (^§^*F*~1,11~=6.40, *P*\<0.03). (f) The phenotype of BrdU-labeled cells at day 28. Corticosterone treatment significantly reduced the percentage of BrdU cell positive for the mature neuronal marker NeuN at day 28 (^§^*F*~1,11~=31.9, *P*\<0.0001). (g) The phenotype of BrdU-labeled cells at day 28. Corticosterone did not affect the proportion of BrdU cells expressing DCX at day 28. (h) The number of new neurons produced at day 28 calculated using the equation described in Experimental Procedures (data in [Table 1](#tbl1){ref-type="table"}). Corticosterone treatment significantly reduced the number of new neurons produced in the dentate gyrus 28 days after BrdU labeling (^§^*F*~1,11~=14.4, *P*\<0.004).](gr1){#fig1}

![(a) Diagram depicting phased (9 days) corticosterone treatment for the seven groups over 27 days. (b) Corticosterone during period 3 significantly reduced neuronal differentiation (^†^*F*~1,15~=6.8, *P*\<0.02), but not 1 or 2 alone. Giving corticosterone for 18 days or more significantly reduced proliferation (1+2+3: ^§^*F*~1,15~=44.3, *P*\<0.0001; 1+2: ^‡^*F*~1,15~=9.62, *P*\<0.008; 2+3: ^Ψ^*F*~1,15~=12.4, *P*\<0.008). (c) Corticosterone treatment for 18 days or more (1+2 or 2+3 or 1+2+3) significantly reduced the numbers of new neurons 27 days after BrdU labeling (1+2: ^†^*P*\<0.001; 2+3: ^‡^*P*\<0.002; 1+2+3: ^§^*P*\<0.0001).](gr2){#fig2}

![(a) Diagram showing the treatment paradigm for the six groups. (b) Both pre-mitotic and post-mitotic corticosterone significantly reduced neuronal differentiation (pre-mitotic: ^§^*P*\<0.045; post-mitotic: ^†^*P*\<0.0001; ^‡^*P*\<0.001). (c) Both pre-mitotic and post-mitotic corticosterone treatments significantly reduced the number of new neurons formed 28 days after BrdU-labeling (^§^*P*\<0.0001, ^†^*P*\<0.0001, ^‡^*P*\<0.0001). Treating animals with corticosterone before BrdU resulted in fewer new neurons than treating with corticosterone after BrdU (CORT/Oil vs Oil/CORT: ^§^*P*\<0.021).](gr3){#fig3}

![(a) Diagram showing the corticoid manipulations in the different groups of animals. (b, c) There was no observable effect by ADX on differentiation of the newly-formed cells as detected by DCX, NeuN and GFAP at day 7 and day 28. (d) Combining the survival data ([Table 1](#tbl1){ref-type="table"}) revealed that ADX significantly increased the number of new neurons formed in the dentate gyrus 28 days after BrdU labeling (^§^*P*\<0.025).](gr4){#fig4}

![(a) Diagram depicting treatment paradigm for the six groups of rats. (b) Graph showing phenotype of BrdU cells at day 28. There was no difference in differentiation between the four day-28 treatment groups. (c) Combining the neuronal differentiation data with the survival data ([Table 1](#tbl1){ref-type="table"}) showed that ADX, whether before or after BrdU labeling, significantly enhanced the number of new neurons in the dentate gyrus (^§^*P*\<0.034, ^†^*P*\<0.009, ^‡^*P*\<0.0001). ADX prior to BrdU administration gave a higher number of new neurons than ADX after BrdU administration 28 days later (^§^*P*\<0.034).](gr5){#fig5}

###### 

The number of new neurons in the dentate gyrus after the experimental treatments described in the text. This was estimated by **N~Ab~=N~0~×%~Sur~×%~Diff~** where **N~Ab~**=absolute number of new neurons, **N~0~**=number of cells labelled by BrdU 24 hours after labelling, **%~Sur~**=mean percentage surviving BrdU cells (data extracted from [@bib46]) and **%~Diff~**=percentage of BrdU immuno-positive NeuN.

  Experiment   Group       *N*~0~       Mean %~Sur~   Mean %~Diff~   Total new neurons
  ------------ ----------- ------------ ------------- -------------- -------------------
  1            Oil         2187.6±154   50.3±5.0      67.9±2.1       712.0±65.0
               High CORT   2187.6±154   34.4±3.8      47.3±3.1       403.5±42.6
  2            Oil         2187.6±154   72.6±7.3      69.5±2.1       1111±125
               1           2187.6±154   58.3±10.3     65.9±3.0       1010±72.1
               2           2187.6±154   69.9±14.5     62.7±2.8       953±108
               3           2187.6±154   84.1±4.9      59.9±3.1       1019±105
               1+2         2187.6±154   46.0±2.0      58.9±2.7       598±51.3
               2+3         2187.6±154   53.8±2.3      56.6±3.0       657±26.1
               1+2+3       2187.6±154   48.6±3.4      48.4±2.3       513.9±42.7
  3            Oil/Oil     3015±94      51.0±2.4      62.3±3.2       1047±87
               Oil/CORT    3012±94      29.1±1.2      31.6±3.0       273±27
               CORT/Oil    996±79       26.8±4.1      47.8±3.8       120±33
               CORT/CORT   996±79       11.5±2.5      24.5±4.1       39.3±13.7
  4            Sham        2192±251     45.5±1.4      64.2±2.8       626±28.9
               ADX         2192±251     70.0±4.7      58.1±3.0       880±85.1
               ADX Repld   2192±251     41.2±2.8      64.9±5.0       560±42.1
  5            CORT/CORT   2478±265     31.1±3.2      64.6±5.0       606±82.8
               CORT/Chol   2478±265     48.3±2.9      71.3±4.2       844±61
               Chol/CORT   7975±804     20.7±1.5      68.9±6.6       1167±155
               Chol/Chol   7975±804     31.1±3.5      72.2±2.2       1779±191

Note that the total number of new neurons presented in this table were calculated from taking the corresponding %~sur~ and %~diff~ from individual animals and substituting into the equation, and therefore these values may not necessarily be the same as those obtained by simply multiplying the mean percentages from each group.
